Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Molecular Partners AG (ADR) - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
MOLN
Nasdaq
8731
https://www.molecularpartners.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Molecular Partners AG (ADR)
Molecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533’s Proposed Mechanism of Action
- Apr 29th, 2024 3:00 pm
Life Science Cares Launches in Switzerland
- Apr 19th, 2024 3:12 pm
Molecular Partners Announces All Board Proposals Approved at the Annual General Meeting
- Apr 17th, 2024 3:12 pm
Molecular Partners Publishes Invitation to Annual General Meeting 2024
- Mar 26th, 2024 1:26 pm
Molecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023
- Mar 14th, 2024 8:00 pm
The past three years for Molecular Partners (VTX:MOLN) investors has not been profitable
- Mar 13th, 2024 8:58 am
Molecular Partners To Hold Conference Call to Discuss Fourth Quarter and Full Year 2023 Results and Announces Upcoming Investor Presentations
- Mar 1st, 2024 9:00 pm
Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference
- Jan 7th, 2024 9:00 pm
Molecular Partners and Orano Med Announce Co-Development Agreement for Radio-DARPin Therapies
- Jan 5th, 2024 9:00 pm
Retail investors account for 43% of Molecular Partners AG's (VTX:MOLN) ownership, while hedge funds account for 33%
- Dec 22nd, 2023 7:22 am
Molecular Partners to Present at 42nd Annual J.P. Morgan Healthcare Conference and Swiss Investor Conferences
- Dec 14th, 2023 6:00 am
Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual Meeting
- Dec 10th, 2023 5:00 pm
Molecular Partners to Present on DARPin Oncology Innovations at Protein & Antibody Engineering Summit Europe (PEGS)
- Nov 14th, 2023 6:00 am
We're Keeping An Eye On Molecular Partners' (VTX:MOLN) Cash Burn Rate
- Nov 9th, 2023 1:47 pm
Molecular Partners Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 SITC Annual Meeting
- Nov 3rd, 2023 4:00 pm
Molecular Partners to Present Initial Data from Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at the 65th ASH Annual Meeting and Exposition
- Nov 2nd, 2023 6:00 am
Molecular Partners to Participate in the TD Cowen 7th Annual Fall Oncology Innovation Summit
- Nov 1st, 2023 6:00 am
Molecular Partners Interim Management Statement Q3 2023: Continued Validation Seen Across the DARPin Portfolio
- Oct 26th, 2023 8:00 pm
Shareholders in Molecular Partners (VTX:MOLN) are in the red if they invested five years ago
- Oct 5th, 2023 8:14 am
Molecular Partners Presents New Data on its Radio DARPin Therapy (RDT) Platform at the EANM 2023 Annual Meeting
- Sep 13th, 2023 5:00 am
Scroll